

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 28015

Title: Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C

Reviewer's code: 03538227

Reviewer's country: Brazil

Science editor: Jing Yu

Date sent for review: 2016-06-28 21:51

Date reviewed: 2016-07-06 09:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript is very well written and clearly states its aims and conclusions. Some necessary minor corrections are pointed here: - The analysis of IL28B gene polymorphism should not be written as plural form because, in fact, just one SNP (rs12979860) was genotyped. For example, "Genetic polymorphism in the IL28B gene (rs12979860) were investigated using Custom TaqMan 5' allelic discrimination assay [...]" should be written with WAS instead WERE. (page 7) - Replace "ARN log10IU/mL" by "RNA log10IU/mL" in Table 2. - The following sentence should be written in the past tense: "Presence of any substitutions in positions 70 and 91 in core protein is associated with lower rates of RVR, EVR, SVR and - table 2.". (Page 8) - Table 4 is not necessary, since all the information in the table are already in the text of the Results section

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 28015

Title: Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C

Reviewer's code: 02994632

Reviewer's country: Egypt

Science editor: Jing Yu

Date sent for review: 2016-06-28 21:51

Date reviewed: 2016-07-08 15:08

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

thanks for your study. it looks overall good with some limitations of low number of patients and low SVR. A question is do you think in your country the cost of doing these techniques to detect the mutations will be lower than the cost of DAAs currently available? in other words do you think that doing these mutations will be cost effective? I think you need to add in your discussion and conclusion which group of patients you beleive that doing these mutations will be benefecial or that even though in your country the cost of these techniques is already lower than the cost of the new DAAs. or that is only for academic interest as we still use the pegylated interferon till now.